Advanced search
Publication Cover
Acta Cardiologica Volume 65, 2010 - Issue 4
Submit an article Journal homepage
7
Views
0
CrossRef citations to date
0
Altmetric
Articles

Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: A tissue Doppler study

Serkan OrduDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.Correspondence[email protected]
, MD,
Hakan OzhanDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.
, MD,
Recai AlemdarDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.
, MD,
Mesut AydinDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.
, MD,
Cengiz BasarDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.
, MD,
Onur CaglarDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.
, MD,
Mehmet YaziciDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.
, MD &
Subhan YalcinDept. of Cardiology, Duzce University, Düzce Medical School, Konuralp Düzce, Turkey.
, MD show all
Pages 401-406 | Received 03 Aug 2009, Accepted 29 Apr 2010, Published online: 23 May 2017

References

  • Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and cardio-vascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231–39.
  • Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BY, Welty TK, Lee ET, Devereux RB. The impact of dia-betes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001; 37: 1943–9.
  • Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Gold-stein RA. Congestive heart failure with normal systolic function. Am J Cardiol 1984; 54: 778–82.
  • Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secre-tion in type 2 diabetes. Diabetes Care 2002; 25: 517–23.
  • Tsuji T, Mizushige K, Noma T, Murakami K, Ohmori K, Miyatake A, Kohno M. Pioglitazone improves left ventric-ular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001; 38: 868–74.
  • Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS. Left-ventricular dias-tolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 2003; 19: 487–93.
  • Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y Pioglitazone improves left ven-tricular diastolic function in patients with essential hyper-tension. Am J Hypertens 2005; 18: 949–57.
  • Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL, Sahn DJ, Schiller NB, Tajik A, Teichholz LE, Weyman AE. Report of the American society of echocardio-graphy committee on nomenclature and standards in two-dimensional imaging. Circulation 1980: 62: 212–7.
  • Pitale SU, Abraira C, Emanuele NV, McCarren M, Hen-derson WG, Pacold I, Bushnell D, Colwell JA, Nuttall FQ, Levin SR, Sawin CT, Comstock JP, Silbert CK. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Dia-betes Mellitus (VA CSDM). Diabetes Care 2000; 23: 1316–20.
  • Brand FN, Kannel WB, Evans J, Larson MG, Wolf PA. Glucose intolerance, physical signs of peripheral arterydisease, and risk of cardiovascular events: the Framingham Study. Am Heart J1998; 136: 919-27.
  • Lind L, Andersson PE, Andrén B, Hänni A, Lithe11 HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13: 433–8.
  • Kamide K, Nagano M, Nakano N, Yo Y, Kobayashi R, Rakugi H, Higaki J, Ogihara T. Insulin resistance and car-diovascular complications in patients with essential hyper-tension. Am J Hypertens 1996; 9: 1165–71.
  • Miyazato J, Horio T, Takishita S, Kawano Y. Fasting plasma glucose is an independent determinant of left ventricular diastolic dysfunction in nondiabetic patients with treated essential hypertension. Hypertens Res 2002; 25: 403–9.
  • Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405–12.
  • Van Hoeven KH, Factor SM. A comparison of the patho-logical spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82: 848–55.
  • Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H. Alteration in left ventricular dias-tolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899–907.
  • Terui G, Goto T, Katsuta M, Aoki I. Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients. J Cardiol 2006; 48: 263–7.
  • Shargorodsky M, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16: 617–
  • Karagiannis E, Pfiitzner A, Forst T, Liibben G, Roth W, Grabellus M, Flannery M, Schöndorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther 2008; 10: 206–12.
  • Derosa G, Fogari E, Cicero AF, D’Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory mark-ers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007; 30: 387–94.
  • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefeb-vre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz 0, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279–89.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.